Total Payments
$190,876
2024 Payments
$64,023
Companies
29
Transactions
419
Medicare Patients
13,433
Medicare Billing
$945,506
Payment Breakdown by Category
Other$101,475 (53.2%)
Research$59,486 (31.2%)
Food & Beverage$14,098 (7.4%)
Travel$13,360 (7.0%)
Consulting$2,367 (1.2%)
Education$89.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $101,475 | 34 | 53.2% |
| Unspecified | $59,486 | 3 | 31.2% |
| Food and Beverage | $14,098 | 331 | 7.4% |
| Travel and Lodging | $13,360 | 42 | 7.0% |
| Consulting Fee | $2,367 | 7 | 1.2% |
| Education | $89.99 | 2 | 0.0% |
Payments by Type
General
$131,390
416 transactions
Research
$59,486
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $60,091 | 4 | $0 (2024) |
| PFIZER INC. | $59,784 | 50 | $0 (2020) |
| E.R. Squibb & Sons, L.L.C. | $49,314 | 37 | $0 (2020) |
| Medtronic Vascular, Inc. | $8,504 | 65 | $0 (2020) |
| Boston Scientific Corporation | $4,734 | 95 | $0 (2024) |
| Medtronic, Inc. | $2,848 | 44 | $0 (2024) |
| ATRICURE, INC. | $1,782 | 27 | $0 (2024) |
| Abbott Laboratories | $1,528 | 43 | $0 (2024) |
| Biosense Webster, Inc. | $537.01 | 10 | $0 (2024) |
| BIOTRONIK INC. | $389.33 | 16 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $64,023 | 98 | Eli Lilly and Company ($60,091) |
| 2023 | $5,124 | 89 | Boston Scientific Corporation ($2,351) |
| 2022 | $1,311 | 28 | Medtronic, Inc. ($535.57) |
| 2021 | $325.25 | 12 | ATRICURE, INC. ($158.10) |
| 2020 | $3,948 | 18 | E.R. Squibb & Sons, L.L.C. ($3,621) |
| 2019 | $30,928 | 48 | PFIZER INC. ($22,973) |
| 2018 | $39,634 | 69 | PFIZER INC. ($22,301) |
| 2017 | $45,582 | 57 | E.R. Squibb & Sons, L.L.C. ($29,568) |
All Payment Transactions
419 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Cardiac Rhythm Management | ||||||
| 12/18/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 12/11/2024 | ATRICURE, INC. | EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) | Food and Beverage | In-kind items and services | $5.95 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/08/2024 | Medtronic, Inc. | AZURE XT DR MRI SURESCAN (Device) | Food and Beverage | In-kind items and services | $21.61 | General |
| Category: Pacemakers | ||||||
| 12/06/2024 | ATRICURE, INC. | EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) | Food and Beverage | In-kind items and services | $47.98 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/04/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $16.58 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 11/29/2024 | Abbott Laboratories | JOT DX (Device) | Food and Beverage | In-kind items and services | $179.94 | General |
| Category: Cardiac Rhythm Management | ||||||
| 11/25/2024 | ATRICURE, INC. | EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) | Food and Beverage | In-kind items and services | $51.80 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/20/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 11/06/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 11/05/2024 | Abbott Laboratories | AMPLATZER TALISMAN (Device) | Food and Beverage | In-kind items and services | $10.56 | General |
| Category: Structural Heart | ||||||
| 11/04/2024 | Abbott Laboratories | AVEIR (Device) | Food and Beverage | In-kind items and services | $166.73 | General |
| Category: Cardiac Rhythm Management | ||||||
| 10/31/2024 | ATRICURE, INC. | EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) | Food and Beverage | In-kind items and services | $27.80 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/31/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 10/30/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 10/23/2024 | Boston Scientific Corporation | VersaCross Large Access Solution (Device) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: VersaCross Large Access Solution_ICG | ||||||
| 10/16/2024 | Boston Scientific Corporation | VersaCross Access Solution (Device) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: VersaCross Access Solution_ICG | ||||||
| 10/10/2024 | Boston Scientific Corporation | LUX-Dx Insertable Cardiac Monitor (Device) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: LUX-Dx_CRM | ||||||
| 10/04/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $74.44 | General |
| Category: Medical Device | ||||||
| 10/02/2024 | Boston Scientific Corporation | WATCHMAN FLX (Device) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: WATCHMAN FLX_IC | ||||||
| 09/27/2024 | Philips North America LLC | (CK4) MCOT (Device) | Food and Beverage | Cash or cash equivalent | $56.87 | General |
| Category: Medical Device | ||||||
| 09/25/2024 | Medtronic, Inc. | PULSESELECT (Device) | Food and Beverage | In-kind items and services | $4.91 | General |
| Category: Ablation | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $37,519.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $16,528.00 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $5,439.00 | Research |
| Study: A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) | Eli Lilly and Company | $37,519 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) | Eli Lilly and Company | $16,528 | 1 |
| A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) | Eli Lilly and Company | $5,439 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 43 | 2,863 | 3,264 | $693,549 | $173,674 |
| 2022 | 44 | 2,799 | 3,393 | $648,008 | $175,679 |
| 2021 | 53 | 3,985 | 4,927 | $1.7M | $313,843 |
| 2020 | 51 | 3,786 | 4,398 | $1.4M | $282,308 |
Total Patients
13,433
Total Services
15,982
Medicare Billing
$945,506
Procedure Codes
192
All Medicare Procedures & Services
192 procedure records from CMS Medicare Utilization — Page 1 of 8
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 93656 | Comprehensive electrophysiologic evaluation with catheter destruction of abnormality causing atrial fibrillation (uncoordinated contraction of upper chambers of heart) by pulmonary vein isolation | Facility | 2023 | 31 | 31 | $87,916 | $22,261 | 25.3% |
| 33208 | Insertion of pacemaker and upper and lower heart chamber electrode | Facility | 2023 | 44 | 44 | $56,375 | $17,161 | 30.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 174 | 189 | $54,999 | $15,668 | 28.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 109 | 116 | $51,300 | $14,187 | 27.7% |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and tec | Office | 2023 | 235 | 324 | $17,820 | $13,229 | 74.2% |
| 93653 | Comprehensive electrophysiologic evaluation with catheter destruction of abnormality of upper chamber of heart causing supraventricular tachycardia (rapid heart rate) | Facility | 2023 | 13 | 13 | $27,625 | $8,262 | 29.9% |
| 93650 | Destruction of heart conduction tissue to create heart block | Facility | 2023 | 17 | 17 | $25,891 | $7,414 | 28.6% |
| 93298 | Evaluation of cardiac rhythm monitor system, remote up to 30 days | Office | 2023 | 210 | 298 | $23,840 | $5,702 | 23.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 46 | 59 | $16,697 | $5,462 | 32.7% |
| 93296 | Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | Office | 2023 | 320 | 328 | $31,160 | $5,147 | 16.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 38 | 38 | $21,580 | $4,993 | 23.1% |
| 93294 | Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | Office | 2023 | 223 | 229 | $22,900 | $4,935 | 21.6% |
| 33225 | Insertion of left lower heart electrode for pacemaker or defibrillator | Facility | 2023 | 14 | 14 | $16,156 | $4,921 | 30.5% |
| 33274 | Insertion of permanent leadless pacemaker using imaging guidance | Facility | 2023 | 15 | 15 | $19,845 | $4,676 | 23.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 345 | 454 | $42,222 | $4,525 | 10.7% |
| 93288 | Evaluation of single, dual, multiple lead or leadless pacemaker system | Office | 2023 | 109 | 114 | $12,996 | $4,324 | 33.3% |
| 33228 | Removal and replacement of dual lead permanent pacemaker | Facility | 2023 | 11 | 11 | $10,181 | $2,973 | 29.2% |
| 93312 | Ultrasound of heart with probe in esophagus, with report | Facility | 2023 | 32 | 33 | $15,510 | $2,732 | 17.6% |
| 93295 | Evaluation of single, dual, or multiple lead implantable defibrillator system, remote up to 90 days | Office | 2023 | 97 | 99 | $17,820 | $2,593 | 14.5% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 36 | 37 | $6,512 | $2,198 | 33.8% |
| 93297 | Evaluation of implantable heart and blood vessel monitoring system, remote up to 30 days | Office | 2023 | 107 | 117 | $8,190 | $2,125 | 25.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $7,672 | $2,056 | 26.8% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 40 | 45 | $28,485 | $2,000 | 7.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $7,980 | $1,921 | 24.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 27 | $5,061 | $1,567 | 31.0% |
About Dr. William Smith, MD
Dr. William Smith, MD is a Clinical Cardiac Electrophysiology healthcare provider based in Wilmington, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144338161.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. William Smith, MD has received a total of $190,876 in payments from pharmaceutical and medical device companies, with $64,023 received in 2024. These payments were reported across 419 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($101,475).
As a Medicare-enrolled provider, Smith has provided services to 13,433 Medicare beneficiaries, totaling 15,982 services with total Medicare billing of $945,506. Data is available for 4 years (2020–2023), covering 192 distinct procedure/service records.
Ad
Practice Information
- Specialty Clinical Cardiac Electrophysiology
- Location Wilmington, NC
- Active Since 08/29/2006
- Last Updated 03/15/2022
- Taxonomy Code 207RC0001X
- Entity Type Individual
- NPI Number 1144338161
Products in Payments
- ELIQUIS (Drug) $109,079
- Arctic Front (Device) $5,644
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX (Device) $1,340
- RHYTHMIA (Device) $892.41
- WATCHMAN FLX (Device) $695.29
- MyCareLink Smart (Device) $676.75
- INGEVITY+ (Device) $625.00
- Claria MRI (Device) $526.60
- WATCHMAN Access System (Device) $479.36
- AZURE XT DR MRI SURESCAN (Device) $465.57
- AVEIR (Device) $426.39
- OLL2, OSL2, ASU2, ASB3 (Device) $425.60
- CareLink (Device) $411.25
- Advisa (Device) $303.31
- JOT DX (Device) $287.72
- COBALT DR MRI SURESCAN (Device) $282.02
- PULSESELECT (Device) $250.16
- Micra (Device) $249.50
- DIAMONDTEMP BIDIRECTIONAL ABLATION CATHETER (Device) $247.92
- QDOT MICRO Catheter (Device) $245.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Clinical Cardiac Electrophysiology Doctors in Wilmington
Dr. Craig Mccotter, Md, MD
Clinical Cardiac Electrophysiology — Payments: $124,043
Clinical Cardiac Electrophysiology $124,043
Carlos Arrieta Garcia, Md, MD
Clinical Cardiac Electrophysiology — Payments: $67,717
Clinical Cardiac Electrophysiology $67,717
Joseph Pennington, M.d, M.D
Clinical Cardiac Electrophysiology — Payments: $18,986
Clinical Cardiac Electrophysiology $18,986
Praful Patel, Md, MD
Clinical Cardiac Electrophysiology — Payments: $17,478
Clinical Cardiac Electrophysiology $17,478
Michael Yarnoz, Md, MD
Clinical Cardiac Electrophysiology — Payments: $10,846
Clinical Cardiac Electrophysiology $10,846